Recudon 5 mg/ml + 0.25 mg/ml solution for injection for horses and dogs

Authorised

- Levomethadone hydrochloride
- Fenpipramide hydrochloride

Product identification

Medicine name:

Recudon 5 mg/ml + 0.25 mg/ml solution for injection for horses and dogs Recudon, 5 mg/ml + 0,25 mg/ml, injekcinis tirpalas arkliams ir šunims

Active substance:

Levomethadone hydrochloride Fenpipramide hydrochloride

Target species:

Horse Dog

Route of administration: Intravenous use

Product details

Active substance and strength:

Levomethadone hydrochloride

5.00 milligram(s) / 1.00 millilitre(s)

Fenpipramide hydrochloride 0.25 milligram(s) / 1.00 millilitre(s)

Pharmaceutical form:

Solution for injection

Withdrawal period by route of administration: Intravenous use:

Horse

- Meat and offal. 3 day

Dog

•

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QN02AC52

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Lithuania

Package description:

Cardboard box with 1 clear glass (Type I) vial of 50 ml with a coated bromobutyl rubber stopper and aluminium cap.

Cardboard box with 1 clear glass (Type I) vial of 30 ml with a coated bromobutyl rubber stopper and aluminium cap.

Cardboard box with 1 clear glass (Type I) vial of 10 ml with a coated bromobutyl rubber stopper and aluminium cap.

Cardboard box with 1 clear glass (Type I) vial of 5 ml (in a 10 ml sized vial) with a coated bromobutyl rubber stopper and aluminium cap.

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Hybrid application - change in strength (Article 19(1)(a) of Regulation (EU) 2019/6)

Marketing authorisation holder:

Alfasan Nederland B.V.

Marketing authorisation date:

1/08/2023

Manufacturing sites for batch release:

Alfasan Nederland B.V.

Responsible authority: State Food And Veterinary Service

Authorisation number: LT/2/23/2767/001-004

Date of authorisation status change:

1/08/2023

Reference member state: Netherlands

Procedure number: NL/V/0384/002

Concerned member states:

Austria Belgium Bulgaria Croatia Cyprus Czechia Denmark Estonia Finland France Germany Greece Hungary Ireland Italy Latvia Lithuania Luxembourg Norway Poland Portugal Romania Slovakia Slovenia Spain Sweden United Kingdom (Northern Ireland) To consult adverse reactions on veterinary medicinal products please go to <u>www.adrreports.eu/vet</u>

Documents

Combined File of all Documents

This document does not exist in this language (English). You can find it in another language below.

Source URL: https://medicines.health.europa.eu/veterinary/600000986369